In contrast, regarding prostate cancer, ANKRD22 is lowly expressed in the tumor group relative to the normal group, and the unfavorable correlation between ANKRD22 and the survival outcome of the patients was identified. Here, ANKRD22 is linked to prostate carcinoma.